home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3134.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
51 lines
Document 3134
DOCN M94A3134
TI Clinical progression in HIV1 and HIV2 infection.
DT 9412
AU Vasconcelos C; Castro-Melo J; Carvalho MF; Santos E; Cerveira C;
Sarmento R; Marques R; Campos M; Servico de Imunologia, Hosp. Sto.
Antonio, Porto, Portugal.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):146 (abstract no. PB0010). Unique
Identifier : AIDSLINE ICA10/94369441
AB INTRODUCTION, POPULATION AND METHODS: A rate of clinical progression
slower for HIV2 than for HIV1 has been generally reported but never
substantiated. In the present study the clinical evolution, evaluated by
Walter Reed staging (WR 1 to 6), was studied by actuarial curves in HIV1
(n = 50) and HIV2 (n = 36) patients matched by age and sex, selected
from a larger cohort comprising patients from a variety of risk groups
studied periodically before and after AZT antiretroviral therapy
(anti-HIV). RESULTS: In patients before anti-HIV (HIV1 = 42; HIV2 = 31),
progression to [WR5 or to WR6], but not to [WR6], was significantly
different in the two groups (p = 0.002); in all patients, irrespectively
of anti-HIV, progression to [WR5 or to WR6] or to [WR6] was also
significantly different (p = 0.001 and p = 0.003 respectively).
Progression to low numbers of CD4 cells (< 300/mm3) and to initiation of
anti-HIV was not significantly different in HIV1 and HIV2. DISCUSSION:
Our results provide evidence for a slower clinical course in HIV2
infection. The recognized incapacity of AZT to significantly alter the
clinical course of HIV infection, legitimates that our results are taken
as representative of HIV1 and HIV2 diseases irrespective of the
treatment status. The similar rates of progression of HIV1 and HIV2
patients to low numbers of CD4 cells explains the similar rate of
progression to initiation of anti-HIV which is timed by the numbers of
CD4 cells. The contrast of a similar course of immunological parameters
with the observed significant difference in the progression to late
stages of disease, for HIV2 as compared with HIV1, confirms our clinical
experience of a slower clinical progression with a similar decay in CD4
cells. This may explain the contrast with previous reports on the
evolution of immunological parameters in patients at the same clinical
stage (what our results show to correspond to different time points for
HIV1 and HIV2 disease) and suggests that, with current criteria, HIV2
patients start anti-HIV earlier in the disease. The latter fact would
account for the low number of non-treated HIV2 patients in WR6 and could
explain that their progression to WR6 is non-significantly different
from HIV1.
DE Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PHYSIOPATHOLOGY
Actuarial Analysis Age Factors Comparative Study Female Human HIV
Seropositivity/IMMUNOLOGY/*PHYSIOPATHOLOGY *HIV-1 *HIV-2 Male Sex
Factors T4 Lymphocytes MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).